Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Twist Bioscience Corporation (TWST) Tops Q4 EPS by 16c, Revenues Beat
November 23, 2020 7:25 AM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($0.54), $0.16 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $32.43 million versus the consensus estimate of $22.67 million.
FISCAL 2020 FOURTH QUARTER FINANCIAL RESULTS
Orders: Total orders received for the fourth quarter of fiscal 2020 were $42.7 million, compared to $20.0 million for the same period of fiscal 2019.Revenue: Total revenues were $32.4 million for the fourth quarter of fiscal 2020 compared to $15.7 million for the same period of fiscal 2019.Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2020 was $17.6 million... More